Latest Neuraminidase inhibitors Stories
BIRMINGHAM, Ala., Jan. 13 /PRNewswire-FirstCall/ -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that its partner, Shionogi & Co., Ltd. has received marketing and manufacturing approval for intravenous (i.v.) peramivir to treat patients with influenza in Japan.
MEXICO CITY and BIRMINGHAM, Ala., Jan.
BIRMINGHAM, Ala., Jan. 12 /PRNewswire-FirstCall/ -- BioCryst Pharmaceuticals, Inc.
BIRMINGHAM, Ala., Jan. 11 /PRNewswire-FirstCall/ -- BioCryst Pharmaceuticals, Inc.
BIRMINGHAM, Ala., Jan. 8 /PRNewswire-FirstCall/ -- BioCryst Pharmaceuticals, Inc.
SAN DIEGO, Jan. 7 /PRNewswire/ -- NexBio, Inc. announced today the initiation of a double blind placebo controlled multi-center trial in the U.S. and Mexico of DAS181 (FludaseÂ®) for the treatment of laboratory confirmed influenza infection.
A massive, data-crunching computer search program that matches fragments of potential drug molecules to the known shapes of viral surface proteins has identified several FDA-approved drugs that could be the basis for new medicines -- if emerging viruses such as the H5N1(avian flu) or H1N1/09 (swine flu) develop resistance to current antiviral therapies.
NEW YORK, Dec. 3 /PRNewswire/ -- According to the World Health Organization, the human H1N1/09 Type A influenza ("Swine Flu") has reached a pandemic level. Over 500,000 cases have been confirmed worldwide with at least 6,500 fatalities.
SOUTH SAN FRANCISCO, Calif., Dec. 2 /PRNewswirel/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has begun shipping additional quantities of TamifluÂ® (oseltamivir phosphate) oral suspension (liquid).
EMERYVILLE, Calif., Nov.
More Images (1 images) »